Sparrow Pharmaceuticals
Targeted cardiometabolic therapeutics
- Headquarters
- Portland, Oregon
- Business Model
- B2B
- Website
- sparrowpharma.com
- Total Funding
- $217.0M
- Last Round
- $95.0M Series BSep 2025
About
Leveraging scientific insights into the intracellular regulation of cortisol, Sparrow is pioneering a precision approach to cardiometabolic disease. Their lead candidate, clofutriben, is a highly potent HSD-1 inhibitor designed to reduce elevated intracellular cortisol, addressing impaired glucose control in millions of patients with difficult-to-control type 2 diabetes.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account